A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

  • Hodge, Alex, (Primary Chief Investigator (PCI))

Project: Research

StatusActive
Effective start/end date20/09/1919/09/24

Keywords

  • phase 3 study
  • clinical trial
  • treatment efficacy
  • cirrhosis